BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 155
- Registration Number
- NCT00289627
- Locations
- ๐บ๐ฆ
Local Institution, Uzhgorod, Ukraine
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Conditions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 144
- Registration Number
- NCT00287547
- Locations
- ๐บ๐ธ
Local Institution, Burlington, Vermont, United States
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT00284804
- Locations
- ๐บ๐ธ
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
๐บ๐ธCalifornia Oncology of the Central Valley, Fresno, California, United States
๐บ๐ธAmerican Health Network of Indiana, Indianapolis, Indiana, United States
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00279760
- Locations
- ๐ฌ๐ง
Local Institution, Leeds, United Kingdom
๐ง๐ชLocal Instiution, Bruxelles, Belgium
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00279734
- Locations
- ๐บ๐ธ
Qutintiles Phase I Services, Lenexa, Kansas, United States
๐บ๐ธPPD Development, Austin, Texas, United States
๐บ๐ธParexel International Corp, Baltimore, Maryland, United States
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT00277225
- Locations
- ๐บ๐ธ
California Clinical Trials Medical Group, Beverly Hills, California, United States
Comparability DE vs CD-CHO1
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00277199
- Locations
- ๐ฌ๐ง
Inveresk Clinical Research, Edinburgh, United Kingdom
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1057
- Registration Number
- NCT00272779
- Locations
- ๐ฌ๐ง
Local Institution, Manchester, Greater Manchester, United Kingdom
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
- Conditions
- Interventions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00261365
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center, Palm Springs, California, United States
๐บ๐ธThe Angeles Clinic And Research Institution, Santa Monica, California, United States
๐ธ๐ชLocal Institution, Stockholm, Sweden
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
- Conditions
- Interventions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 738
- Registration Number
- NCT00256750
- Locations
- ๐บ๐ธ
Cedars Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธEmory University Hospital, Atlanta, Georgia, United States
๐บ๐ธMedical College Of Georgia, Augusta, Georgia, United States